Search Results - "Breast Neoplasms pathology"

Contributors: Hôpitaux Universitaires de Genève (HUG), Institut Curie [Paris], Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Universidade do Porto, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Fundo Regional para a Ciência e Tecnologia, FRCT, Funding AFV received support from a Mayent-Rothschild fellowship from Institut Curie, France and IPATIMUP/Fundação para a Ciência e Tecnologia, Portugal.

Source: Modern pathology, Vol. 33, No 11 (2020) pp. 2198-2207
Modern Pathology
Modern Pathology, Nature Publishing Group: Open Access Hybrid Model Option B, 2020, 33 (11), pp.2198-2207. ⟨10.1038/s41379-020-0561-9⟩

Subject Terms: Pathology and Forensic Medicine, Oncology, medicine.medical_specialty, medicine, Invasive lobular carcinoma, medicine.disease, Lymph node, medicine.anatomical_structure, Nottingham Prognostic Index, Internal medicine, Estrogen receptor, Biomarker (medicine), Survival analysis, Pathology, Tumor-infiltrating lymphocytes, Invasive Lobular Breast Carcinoma, business.industry, business, ddc:616.07, Age Factors, Breast Neoplasms / immunology, Breast Neoplasms / metabolism, Breast Neoplasms / mortality, Breast Neoplasms / pathology, Carcinoma, Lobular / immunology, Carcinoma, Lobular / metabolism, Carcinoma, Lobular / mortality, Carcinoma, Lobular / pathology, Female, Humans, Lymphocytes, Tumor-Infiltrating / immunology, Lymphocytes, Tumor-Infiltrating / pathology, Middle Aged, Prognosis, Receptor, ErbB-2 / metabolism, Receptors, Estrogen / metabolism, Receptors, Progesterone / metabolism, Retrospective Studies, Survival Rate, [SDV]Life Sciences [q-bio]

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e706a06496cec3a93a064f39656fada
http://www.nature.com/articles/s41379-020-0561-9.pdf

4

Granular Cell Tumor: A Rare Breast Lesion

Authors: Sofia Dutra, José Carlos Marques

Source: Acta Médica Portuguesa, Vol 33, Iss 1, Pp 61-64 (2020)

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::657ab85c8c5ade3c246df70f88c4bfae
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10279

5

a nationwide study of 4901 patients in the Netherlands

Authors: van Dooijeweert, Carmen, van Diest, Paul J, Willems, Stefan M, Kuijpers, Chantal C H J, Overbeek, Lucy I H, Deckers, Ivette A G

Source: Breast Cancer Research and Treatment. 174(2):479-488

Subject Terms: Aged, Breast Neoplasms/pathology, Carcinoma, Intraductal, Noninfiltrating/pathology, Female, Humans, Laboratories/standards, Logistic Models, Middle Aged, Neoplasm Grading, Netherlands, Odds Ratio, Registries, skin and connective tissue diseases

Access URL: https://explore.openaire.eu/search/publication?articleId=dris___00893::ac1bfa3535443958214e7abc28affd05

6

A Misdiagnosis of a Breast Tumor: Histology Solves It

Authors: Inês Morujão, Susana Nunes, Nádia Silva, João Vasco Barreira, Ana Correia

Source: Gazeta Médica, Vol 7, Iss 3 (2020)

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a380cd3f755a51c014eba31802cdefb
https://www.gazetamedica.pt/index.php/gazeta/article/view/316

7

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells

Contributors: Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge [UK] (CAM), Department of Biochemistry [Cambridge], Cambridge University Hospitals - NHS (CUH), Intégrité du génome, immunité et cancer - Genome integrity, Immunity and Cancer, Institut Pasteur [Paris], Netherlands Cancer Institute (NKI), Antoni van Leeuwenhoek Hospital, Cancer Research UK Cambridge Institute [Cambridge, Royaume-Uni] (CRUK), Institute of Molecular Biology (IMB), Johannes Gutenberg - Universität Mainz (JGU), Wellcome Trust Sanger Institute [Hinxton, UK], AstraZeneca US [Waltham, USA], AstraZeneca [Cambridge, UK], The Wellcome Trust Sanger Institute [Cambridge], Vall d'Hebron Institute of Oncology [Barcelone] (VHIO), Vall d'Hebron University Hospital [Barcelona], The SPJ lab is largely funded by a Cancer Research UK (CRUK) Program Grant, C6/A18796, and a Wellcome Trust (WT) Investigator Award, 206388/Z/17/Z. Core infrastructure funding was provided by CRUK grant C6946/A24843 and WT grant WT203144. S.P.J. receives a salary from the University of Cambridge. H.D. is funded by WT Clinical Fellowship 206721/Z/17/Z. TWC was supported by a Cambridge International Scholarship. D.P. is funded by Cancer Research UK studentship C6/A21454. The P.B. lab is supported by the Emmy Noether Program (BE 5342/1-1) from the German Research Foundation and a Marie Curie Career Integration Grant from the European Commission (630763). The L.P. lab is funded by the WT (investigator award 104641/Z/14/Z) and the Medical Research Council (project grant MR/N000161/1). The C.C. lab was supported with funding from CRUK. The J.J. lab was supported by the European Research Council grant ERC-StG 311565, The Dutch Cancer Society (KWF) grant KWF 10999, and the Netherlands Organization for Scientific Research (NWO) as part of the National Roadmap Large-scale Research Facilities of the Netherlands, Proteins@Work (project no. 184.032.201 to the Proteomics Facility of the Netherlands Cancer Institute). The L.D. lab is funded by the Institut Pasteur, the Institut National du Cancer (no. PLBIO16-181) and the European Research Council (starting grant agreement no. 310917). W.W. is part of the Pasteur–Paris University (PPU) International PhD program and this project received funding from the CNBG company, China. Q.W. is funded by the Wellcome Trust (200814/Z/16/Z ). The V.S. lab work was funded by the Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (PI17-01080 to VS), the European Research Area-NET, Transcan-2 (AC15/00063), a non-commercial research agreement with AstraZeneca UK, and structural funds from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 540) and the Orozco Family. V.S. received a salary and travel support to C.C.’s lab from ISCIII (CP14/00228, MV15/00041) and the FERO Foundation., The authors thank all S.P.J. laboratory members for support and advice, and Cambridge colleagues N. Lawrence for OMX super-resolution microscopy support and R. Butler for help with computational image analyses and programming. The authors also thank S. Selivanova and S. Hough for help with plasmid amplification, sample preparation and tissue culture maintenance, K. Dry for extensive editorial assistance, F. Muñoz-Martinez for assistance with CRISPR–Cas9 knockout generation, L. Radu for assistance with protein purification, C. Lord (Institute of Cancer Research, London) for SUM149PT cells, D. Durocher (University of Toronto, Canada) for U2OS LacSceIII cells, F. Alt (Harvard University, USA) for CH12F3 cells and 53bp1 knockout CH12F3 cell clones, T. Honjo (Kyoto University, Japan) for permission to use the CH12F3 cell line, and J. Serrat in the Jacobs lab for technical assistance

Source: Nature cell biology
Nature Cell Biology
Nature Cell Biology, Nature Publishing Group, 2018, 20 (8), pp.954-965. ⟨10.1038/s41556-018-0140-1⟩

Subject Terms: Article, DNA damage and repair, Cancer, MESH: Animals, MESH: BRCA1 Protein / deficiency, MESH: Drug Resistance, Neoplasm* / genetics, MESH: Female, MESH: BRCA1 Protein / genetics, MESH: HEK293 Cells, MESH: Humans, MESH: Mad2 Proteins / genetics, MESH: Mad2 Proteins / metabolism, MESH: Mice, MESH: Multiprotein Complexes, MESH: Osteosarcoma / drug therapy, MESH: Breast Neoplasms / pathology, MESH: Osteosarcoma / genetics, MESH: Osteosarcoma / metabolism, MESH: Osteosarcoma / pathology, MESH: Bone Neoplasms / drug therapy, MESH: Ovarian Neoplasms / drug therapy, MESH: Ovarian Neoplasms / genetics, MESH: Ovarian Neoplasms / metabolism, MESH: Ovarian Neoplasms / pathology, MESH: Poly(ADP-ribose) Polymerase Inhibitors / pharmacology, MESH: Proteins / genetics, MESH: Cell Cycle Proteins, MESH: Proteins / metabolism, MESH: Recombinational DNA Repair, MESH: Telomere-Binding Proteins / genetics, MESH: Telomere-Binding Proteins / metabolism, MESH: Bone Neoplasms / genetics, MESH: Tumor Suppressor p53-Binding Protein 1 / genetics, MESH: Tumor Suppressor p53-Binding Protein 1 / metabolism, MESH: Xenograft Model Antitumor Assays, MESH: Bone Neoplasms / metabolism, MESH: Bone Neoplasms / pathology, MESH: Cell Line, Tumor, MESH: Breast Neoplasms / drug therapy, MESH: Breast Neoplasms / genetics, MESH: Breast Neoplasms / metabolism, MESH: Cisplatin / pharmacology, MESH: DNA Breaks, Double-Stranded, MESH: DNA End-Joining Repair, MESH: DNA-Binding Proteins, MESH: Dose-Response Relationship, Drug, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, [SDV.GEN]Life Sciences [q-bio]/Genetics, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Cell Biology, DNA, chemistry.chemical_compound, chemistry, Homologous recombination, Polymerase, biology.protein, biology, Oligonucleotide, Telomere-binding protein, HEK 293 cells, RAD51, Cell biology, Poly (ADP-Ribose) Polymerase Inhibitor, Cell Line, Tumor, Animals, Humans, Mice, Osteosarcoma, Bone Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Cisplatin, Multiprotein Complexes, Proteins, Cell Cycle Proteins, DNA-Binding Proteins, Telomere-Binding Proteins, BRCA1 Protein, Xenograft Model Antitumor Assays, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Female, DNA Breaks, Double-Stranded, HEK293 Cells, DNA End-Joining Repair, Recombinational DNA Repair, Mad2 Proteins, Poly(ADP-ribose) Polymerase Inhibitors, Tumor Suppressor p53-Binding Protein 1, skin and connective tissue diseases

File Description: application/pdf; Print-Electronic

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94c03882fb1aad0056e71d15c34e8ed4
http://europepmc.org/articles/PMC6145444

8

Patient reported cosmetic outcome after vacuum assisted excision of benign breast lesions: a cross-sectional study

Authors: Gerson M. Struik, Renata H J A Sinke, Taco M. Klem, Erwin Birnie, Ali Ghandi, Elles M F van de Voort

Contributors: Health Psychology Research (HPR)

Source: British journal of radiology, 93(1114):20190994. BRITISH INST RADIOLOGY
Br J Radiol

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46a42cbeb122c0228f7a913aefd547b
https://research.rug.nl/en/publications/patient-reported-cosmetic-outcome-after-vacuum-assisted-excision-of-benign-breast-lesions(82a8f5e9-3ffc-4b1f-a25c-f60cbc0068bf).html

9

Patient reported cosmetic outcome after vacuum assisted excision of benign breast lesions

Authors: van de Voort, Elles M F, Klem, Taco M A L, Struik, Gerson M, Birnie, Erwin, Sinke, Renata H J A, Ghandi, Ali

Source: British journal of radiology. 93(1114)

Subject Terms: Adult, Aged, Biopsy, Large-Core Needle, Breast Neoplasms/pathology, Cross-Sectional Studies, Esthetics, Female, Humans, Middle Aged, Netherlands, Patient Reported Outcome Measures, Vacuum

Access URL: https://explore.openaire.eu/search/publication?articleId=dris___00893::7d96e7c56b637757470132c686c62bc1

10

Academic Journal

Metastatic eyelid disease associated with primary breast carcinoma: case report

Authors: Fonseca Júnior, Nilson Lopes da, Lucci, Lucia Miriam Dumont, Cha, Sung Bok, Rossetti, Claudia, Rehder, José Ricardo Carvalho Lima

Source: Arquivos Brasileiros de Oftalmologia. June 2009 72(3)

Subject Terms: Neoplasm metastasis, Eyelid neoplasms/secondary, Carcinoma, Breast neoplasms/pathology

File Description: text/html

Access URL: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492009000300022

Accede al texto completo

11

ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors

Contributors: Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases (LYOS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Génomique Fonctionnelle de Lyon (IGFL), École normale supérieure - Lyon (ENS Lyon)-Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), The University of Sydney, Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Institut Curie, Università Campus Bio-Medico di Roma / University Campus Bio-Medico of Rome ( UCBM), Medizinische Universität Wien = Medical University of Vienna, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Biochemistry [University of Toronto], University of Toronto, Institut de biologie de Lille - IBL (IBLI), Université de Lille, Sciences et Technologies-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Centre National de la Recherche Scientifique (CNRS)-Université de Lille, Droit et Santé, Mécanismes de tumorigenèse et thérapies ciblées, Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Lille, This work was supported by the National Center for Scientific Research (CNRS) to EB, the National Institute of Health and Medical Research (INSERM), the University of Lyon1, La Ligue Nationale (Drôme), Inserm-Transfert (EB). GV was supported by the Labex DEVweCAN, MG, MB by the French National Cancer Institute (INCa), CK by the Marie-Curie-Individual-Fellowship (655777-miR-OMeS). CAP, LC, and MM by CANCER-ID (FP7/2007-2013) and EFPIA., The authors thank Anne Flourens, Cyprien Tilmant, Tina Louadj, and both CeCIL and ALECS platforms (Faculté de Médecine Laennec, Lyon) for their assistance., Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases [LYOS], Institut de Génomique Fonctionnelle de Lyon [IGFL], Ingénierie Moléculaire et Physiopathologie Articulaire [IMoPA], Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) [IAB], Centre de recherche en neurosciences de Lyon [CRNL], Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 [AIDMP], Institut Curie [Paris], Università Campus Bio-Medico di Roma / University Campus Bio-Medico of Rome [ UCBM], Institut de Recherche en Cancérologie de Montpellier [IRCM - U1194 Inserm - UM], Institut de biologie de Lille - IBL [IBLI], Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), IGFL - Institut de Génomique Fonctionnelle de Lyon, Centre Hospitalier de l'Université de Montréal (CHUM), Equipe Impact, Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Centre de Biologie Et de Pathologie Est - Bron Centre médical, Marie Curie Research Institute, MRCI, Genetique Moleculaire des Cancers d'Origine Epitheliale, Institut Curie-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Surgery, Breast Health Center, Medical University Vienna, Institut du Cancer de Montpellier (ICM), Department of Molecular and Medical Genetics, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 (CANTHER), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Biochimie Générale et Médicale, INSERM-CNRS U.189 Faculté de Médecine Lyon-Sud, Centre de Recherche en Géomatique [Laval] (CRG), Université Laval, Swiss Federal Office for the Environment FOEN, Département de Génétique [Institut Curie, Paris] (Unité de Pharmacogénomique), Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Université Grenoble Alpes (UGA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de biologie et chimie des protéines [Lyon] (IBCP), Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]

Source: Oncogene
Oncogene, Nature Publishing Group, 2019, 38 (7), pp.950-964. ⟨10.1038/s41388-018-0579-3 ⟩
Oncogene, Nature Publishing Group, 2019, 38 (7), pp.950-964. ⟨10.1038/s41388-018-0579-3⟩

Subject Terms: MESH: Animals, MESH: Bone Neoplasms/genetics, MESH: Breast Neoplasms/metabolism, MESH: Breast Neoplasms/pathology, MESH: Humans, MESH: Female, MESH: Gene Expression Regulation, Neoplastic, MESH: Mammary Neoplasms, Animal/genetics, MESH: Mammary Neoplasms, Animal/metabolism, MESH: Mammary Neoplasms, Animal/pathology, MESH: Mice, MESH: Mice, Inbred BALB C, MESH: Receptor Activator of Nuclear Factor-kappa B/biosynthesis, MESH: Neoplasm Proteins/genetics, MESH: Neoplasm Proteins/metabolism, MESH: Receptor Activator of Nuclear Factor-kappa B/genetics, MESH: Bone Neoplasms/metabolism, MESH: Receptors, Estrogen/genetics, MESH: Receptors, Estrogen/metabolism, MESH: Bone Neoplasms/pathology, MESH: Breast Neoplasms/genetics, MESH: Bone Neoplasms/secondary, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Animals, Bone Neoplasms/genetics, Breast Neoplasms/metabolism, Breast Neoplasms/pathology, Humans, Female, Gene Expression Regulation, Neoplastic, Mammary Neoplasms, Animal/genetics, Mammary Neoplasms, Animal/metabolism, Mammary Neoplasms, Animal/pathology, Mice, Mice, Inbred BALB C, Receptor Activator of Nuclear Factor-kappa B/biosynthesis, Neoplasm Proteins/genetics, Neoplasm Proteins/metabolism, Receptor Activator of Nuclear Factor-kappa B/genetics, Bone Neoplasms/metabolism, Receptors, Estrogen/genetics, Receptors, Estrogen/metabolism, Bone Neoplasms/pathology, Breast Neoplasms/genetics, Bone Neoplasms/secondary, [SDV]Life Sciences [q-bio], Cancer Research, Genetics, Molecular Biology, Cancer cell, Breast cancer, medicine.disease, medicine, Transcriptome, Primary tumor, Biology, Cancer research, PI3K/AKT/mTOR pathway, RANKL, biology.protein, Circulating tumor cell, Metastatic breast cancer

File Description: application/octet-stream; application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::673afe46894df907867170c048c800d7
https://hal.archives-ouvertes.fr/hal-02353108

12

Radioactive Seed Localization for Nonpalpable Breast Lesions: Program Development & Implementation in Argentina

Authors: María Soledad Muñoz, Carlos Enrique Rossi, Marcelo Muñoz

Source: Revista argentina de radiología, Volume: 83, Issue: 3, Pages: 102-112, Published: SEP 2019

Subject Terms: cáncer de mama/ diagnóstico por imágenes, cáncer de mama/ patología, cáncer de mama/ cirugía, medicina nuclear/ procedimientos, ultrasonografía/ procedimientos, breast neoplasms/ diagnostic imaging, breast neoplasms /pathology, breast, neoplasms/surgery, radionuclide imaging/methods, ultrasonography/ methods, Radiology Nuclear Medicine and imaging, Neoplasms surgery, Humanities, Philosophy

File Description: text/html

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a25630664e81c7bee2cd2e5288b476a0
http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S1852-99922019000300003&lng=en&tlng=en

13

Carbidopa Alters Tryptophan Metabolism in Breast Cancer and Melanoma Cells Leading to the Formation of Indole-3-Acetonitrile, a Pro-Proliferative Metabolite

Authors: Duarte, Diana, Amaro, Filipa, Silva, Isabel, Silva, Dany, Fresco, Paula, Oliveira, José C., Reguengo, Henrique, Gonçalves, Jorge, Vale, Nuno

Contributors: Instituto de Investigação e Inovação em Saúde

Source: Biomolecules
Biomolecules, Vol 9, Iss 9, p 409 (2019)
Volume 9
Issue 9

Subject Terms: Article, indole-3-acetonitrile, tryptophan, carbidopa, MCF-7 cell line, A375 cell line, lcsh:Microbiology, lcsh:QR1-502, Breast Neoplasms / metabolism, Breast Neoplasms / pathology, Carbidopa / pharmacology, Cell Line, Tumor, Cell Proliferation / drug effects, Cell Survival / drug effects, Chromatography, High Pressure Liquid, Female, Humans, Indoles / analysis, Indoles / metabolism, Melanoma / metabolism, Melanoma / pathology, Skin Neoplasms / metabolism, Skin Neoplasms / pathology, Spectrometry, Mass, Electrospray Ionization, Tryptophan / metabolism, Molecular Biology, Biochemistry, Aromatic L-amino acid decarboxylase, Chemistry, Metabolite, chemistry.chemical_compound, Kynureninase, Cancer research, Melanoma, medicine.disease, medicine, Tryptophan, Breast cancer, Enzyme, chemistry.chemical_classification, Carbidopa, medicine.drug, nervous system diseases

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9138061437389dba5962460c6c79f056
http://europepmc.org/articles/PMC6770008

HTML Full Text PDF Full Text

14

Academic Journal

Annual or Biennial Mammography Screening for Women at a Higher Risk with a Family History of Breast Cancer: Prognostic Indicators of Screen-Detected Cancers in New South Wales, Australia

Authors: Randall, Deborah, Morrell, Stephen, Taylor, Richard, Hung, Wai Tak

Source: Cancer Causes & Control. 20(5):559-566

Access URL: https://www.jstor.org/stable/40272021

Accede al texto completo

PDF Full Text

15

Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast : a nationwide study of 4901 patients in the Netherlands

Authors: van Dooijeweert, Carmen, van Diest, Paul J., Willems, Stefan M., Kuijpers, Chantal C. H. J., Overbeek, Lucy I. H., Deckers, Ivette A. G.

Contributors: PMB medici

Source: Breast Cancer Research and Treatment, 174(2), 479. Springer New York
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 174(2), 479-488. SPRINGER

File Description: text/plain

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe6a828646d6ba908a87311d1ab9df7b
https://dspace.library.uu.nl/handle/1874/391824

16

Type I IFN Receptor Signaling Controls IL7-Dependent Accumulation and Activity of Protumoral IL17A-Producing γδT Cells in Breast Cancer

Authors: Daphnée Soulard, François Trottein, Maya Hassane, Christelle Faveeuw, David Dombrowicz, Christophe Paget, Emmanuel C. Patin, Sébastien Fleury

Contributors: Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM), European Genomic Institute for Diabetes - FR 3508 (EGID), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Université Libanaise, Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), This work was supported by the recurrent annual financial support from INSERM. E.C. Patin was supported by a post-doctoral fellowship from the French Institute of Cancer (INCa). C. Paget, S. Fleury, D. Dombrowicz, and C. Faveeuw were supported by INSERM. F. Trottein was supported by CNRS. M. Hassane was the recipient of a doctoral fellowship from the AZM Foundation. We thank the Pasteur Lille animal facility for excellent mouse husbanding. We also thank the BICeL flow cytometry core facility for technical assistance. This work was supported by the 'Institut National du Cancer' (INCa, PLBIO14-155, recipient: C. Paget)., Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires (RNMCD - U1011), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL], Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires [RNMCD - U1011], Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 [CEPR], Centre d’Infection et d’Immunité de Lille - INSERM U1019 - UMR 9017 [CIIL], Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD], Centre d’Infection et d’Immunité de Lille (CIIL) - INSERM U1019 - UMR 9017 [CIIL], Récepteurs nucléaires, maladies cardiovasculaires et diabète [EGID]

Source: Cancer Research
Cancer Research, American Association for Cancer Research, 2018, 78 (1), pp.195-204. ⟨10.1158/0008-5472.CAN-17-1416⟩

Subject Terms: MESH: Animals, MESH: Breast Neoplasms/immunology, MESH: Mice, Inbred BALB C, MESH: Mice, Inbred C57BL, MESH: Receptor, Interferon alpha-beta/genetics, MESH: Receptor, Interferon alpha-beta/immunology, MESH: Receptor, Interferon alpha-beta/metabolism, MESH: Receptors, Antigen, T-Cell, gamma-delta/metabolism, MESH: Signal Transduction, MESH: T-Lymphocyte Subsets/immunology, MESH: T-Lymphocyte Subsets/metabolism, MESH: Tumor Necrosis Factor Receptor Superfamily, Member 7/genetics, MESH: Breast Neoplasms/metabolism, MESH: Tumor Necrosis Factor Receptor Superfamily, Member 7/metabolism, MESH: Breast Neoplasms/pathology, MESH: Female, MESH: Interleukin-17/genetics, MESH: Interleukin-17/metabolism, MESH: Interleukin-7/metabolism, MESH: Lymphocytes, Tumor-Infiltrating/metabolism, MESH: Lymphocytes, Tumor-Infiltrating/pathology, [SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity, [SDV]Life Sciences [q-bio], Animals, Breast Neoplasms/immunology, Mice, Inbred BALB C, Mice, Inbred C57BL, Receptor, Interferon alpha-beta/genetics, Receptor, Interferon alpha-beta/immunology, Receptor, Interferon alpha-beta/metabolism, Receptors, Antigen, T-Cell, gamma-delta/metabolism, Signal Transduction, T-Lymphocyte Subsets/immunology, T-Lymphocyte Subsets/metabolism, Tumor Necrosis Factor Receptor Superfamily, Member 7/genetics, Breast Neoplasms/metabolism, Tumor Necrosis Factor Receptor Superfamily, Member 7/metabolism, Breast Neoplasms/pathology, Female, Interleukin-17/genetics, Interleukin-17/metabolism, Interleukin-7/metabolism, Lymphocytes, Tumor-Infiltrating/metabolism, Lymphocytes, Tumor-Infiltrating/pathology, Cancer Research, Oncology, Immunology, Cancer, medicine.disease, medicine, Tumor progression, Tumor microenvironment, Cancer research, Angiogenesis, T-cell receptor, Breast cancer, Metastasis, Biology, Immune system

File Description: application/octet-stream

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e09b4212303852f721fd35a700bae12
https://www.hal.inserm.fr/inserm-02436039

17

Axillary Surgery Following Neoadjuvant Chemotherapy – Multidisciplinary Guidance From the Association of Breast Surgery, Faculty of Clinical Oncology of the Royal College of Radiologists, UK Breast Cancer Group, National Coordinating Committee for Breast Pathology and British Society of Breast Radiology

Authors: Gandhi, A, Coles, Charlotte, Makris, A, Provenzano, E, Goyal, A, Maxwell, AJ, Doughty, J

Source: Gandhi, A, Coles, C, Makris, A, Provenzano, E, Goyal, A, Maxwell, A J & Doughty, J 2019, ' Axillary Surgery Following Neoadjuvant Chemotherapy-Multidisciplinary Guidance From the Association of Breast Surgery, Faculty of Clinical Oncology of the Royal College of Radiologists, UK Breast Cancer Group, National Coordinating Committee for Breast Pathology and British Society of Breast Radiology ', Clinical oncology (Royal College of Radiologists (Great Britain)), vol. 31, no. 9, pp. 664-668 . https://doi.org/10.1016/j.clon.2019.05.021

File Description: Print-Electronic

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::764499e050c23ff4666e8b8e61b1d0b0

18

Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer

Authors: Felipe Melo Cruz, Lilian Martins Arruda, Auro Del Giglio, Damila Cristina Trufelli, Luana Carolina Ferreira Fiuza Silva, Waldec Jorge David Filho

Source: Einstein
Einstein (São Paulo) v.17 n.1 2019
Einstein (São Paulo)
IIEPAE
instacron:IIEPAE
Einstein (São Paulo), Vol 17, Iss 1

File Description: text/html

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9886656b46deeb84b3885162f2bd15b
http://europepmc.org/articles/PMC6355205

19

ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis

Authors: Dumortier, Mandy, Ladam, Franck, Damour, Isabelle, Vacher, Sophie, Bieche, Ivan, Marchand, Nathalie, de Launoit, Yvan, Tulasne, David, Chotteau-Lelièvre, Anne

Contributors: Mécanismes de la Tumorigénèse et Thérapies Ciblées (M3T) - UMR 8161 (M3T), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), University of Massachusetts Medical School [Worcester] (UMASS), University of Massachusetts System (UMASS), Institut Curie, Institut de biologie de Lille - IBL (IBLI), Université de Lille, Sciences et Technologies-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), This work was supported by the Centre national de la recherche scientifique (CNRS), the Institut Pasteur de Lille, and Institut National de la Santé et de la Recherche Médicale (INSERM), as well as by grants from the Ligue contre le Cancer, comité Aisne and the Association pour la Recherche sur le Cancer., We thank Martine Duterque-Coquillaud, Anne Flourens, and Antonino Bongiovanni for their precious help in IHC experiments. We thank the Microscopy-Imaging-Cytometry Facility of the BioImaging Center Lille Nord-de-France for access to instruments and technical advice., Mécanismes de tumorigenèse et thérapies ciblées, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Département de Génétique [Institut Curie, Paris] (Unité de Pharmacogénomique), Institut Curie [Paris], Institut de biologie de Lille - UMS 3702 (IBL), Université de Lille-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Centre National de la Recherche Scientifique (CNRS)

Source: Breast Cancer Research
Breast Cancer Research, BioMed Central, 2018, 20 (1), pp.73. ⟨10.1186/s13058-018-0992-0⟩
Breast Cancer Research, BioMed Central, 2018, 20, ⟨10.1186/s13058-018-0992-0⟩
Breast Cancer Research, BioMed Central, 2018, 20 (1), ⟨10.1186/s13058-018-0992-0⟩
Breast Cancer Research, Vol 20, Iss 1, Pp 1-18 (2018)
Breast Cancer Research : BCR

Subject Terms: Breast cancer, ETV4, MMP13, Transcription factor, Tumorigenesis, MESH: Adenovirus E1A Proteins/genetics, MESH: Adult, MESH: Neoplasm Invasiveness/pathology, MESH: Prognosis, MESH: Aged, MESH: Proto-Oncogene Proteins/genetics, MESH: Xenograft Model Antitumor Assays, MESH: Aged, 80 and over, MESH: Animals, MESH: Breast Neoplasms/genetics, MESH: Breast Neoplasms/pathology, MESH: Carcinogenesis/genetics, MESH: Cell Proliferation/genetics, MESH: Cell Line, Tumor, MESH: Cell Movement/genetics, MESH: Female, MESH: Gene Expression Regulation, Neoplastic, MESH: Humans, MESH: Matrix Metalloproteinase 13/genetics, MESH: Mice, MESH: Middle Aged, MESH: Neoplasm Invasiveness/genetics, [SDV]Life Sciences [q-bio], [SDV.CAN]Life Sciences [q-bio]/Cancer, Cell growth, Cancer cell, ETS transcription factor family, Carcinogenesis, medicine.disease_cause, medicine, Oncogene, Cancer research, Metastasis, medicine.disease, Biology, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Research Article

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f0aafff2698ee2d18ea8563da34ce40
https://hal.archives-ouvertes.fr/hal-02391607

20

Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer

Authors: Forsare, Carina, Bak, Martin, Falck, Anna-Karin, Grabau, Dorthe, Killander, Fredrika, Malmström, Per, Rydén, Lisa, Stål, Olle, Sundqvist, Marie, Bendahl, Pär-Ola, Fernö, Mårten

Source: BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-12 (2018)
Forsare, C, Bak, M, Falck, A K, Grabau, D, Killander, F, Malmström, P, Rydén, L, Stål, O, Sundqvist, M, Bendahl, P O & Fernö, M 2018, ' Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer ', BMC Cancer, vol. 18, 1226 . https://doi.org/10.1186/s12885-018-5123-x

Subject Terms: Research Article, Breast cancer, Prognostic, Categorical, Continuous, Fractional polynomials, Splines, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Cancer Research, Genetics, Oncology, Internal medicine, medicine.medical_specialty, medicine, Tumor size, Continuous scale, medicine.disease, Gene expression profiling, Proportional hazards model, Age at diagnosis, Lymph, Surgical oncology, business.industry, business, Cancer and Oncology, Cancer och onkologi, Gene Expression Profiling/methods, Prognosis, Breast Neoplasms/pathology, Humans, Middle Aged, Risk Factors, Proportional Hazards Models, Neoplasm Recurrence, Local/pathology, Lymphatic Metastasis/pathology, Lymph Nodes/pathology, Adult, Female

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8059ab9daa88ab89cedc6de4ea56d609
http://europepmc.org/articles/PMC6286551

Refine Results